Fibroscan Study in HCC

N/AActive Not RecruitingNCT01796145

Chinese University of Hong Kong207 enrolled

Overview

In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

207

Conditions

Confirmed Diagnosis of Hepatocellular Carcinoma Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery Child's A to C Cirrhosis

Interventions

FibroscanOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of HCC * Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery 1. For TACE cohort, patients undergoing first cycle TACE are eligible. 2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible. 3. For surgery cohort, patient undergoing surgery are eligible. * Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed * Child's A to Child's C liver function Exclusion Criteria: * ECOG performance status \> 2 * Poorly controlled ascites

Locations (1)

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong

Outcomes

Primary Outcomes

Overall survival

Time frame: 3 years

Secondary Outcomes

Rate and grade of treatment complications

Time frame: 2 years

Liver stiffness (kPa)

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.